Early intravenous thrombolysis with recombinant tissue-type plasminogen activator in vertebrobasilar ischemic stroke. 1998

M Grond, and J Rudolf, and S Schmülling, and C Stenzel, and M Neveling, and W D Heiss
Department of Neurology, University Hospital of Cologne, Germany.

BACKGROUND The optimal therapy of vertebrobasilar ischemic stroke is under debate. In the case of underlying basilar artery occlusion, intra-arterial thrombolysis is recommended. Because this pathologic condition is rarely found and the procedure is time consuming and restricted to specialized centers, the question arises whether early intravenous thrombolysis could also effectively be applied in vertebrobasilar ischemic stroke. OBJECTIVE To determine if early intravenous thrombolysis could be used effectively in vertebrobasilar ischemic stroke. METHODS A case series of 12 consecutive patients with acute vertebrobasilar ischemia were followed up 3 months after thrombolytic treatment at the Department of Neurology of the University Hospital of Cologne, Cologne, Germany, a primary care and referral center. METHODS Patients with clinically diagnosed moderate to severe vertebrobasilar ischemic stroke with clearly determined symptom onset were treated with intravenous recombinant tissue-type plasminogen activator within 3 hours after symptom onset following a protocol similar to that of the National Institute of Neurological Disorders and Stroke study. RESULTS On admission, 7 patients exhibited moderate to severe brainstem symptoms without impairment of consciousness and 5 patients had impairment of consciousness, of whom 2 were comatose. Of 12 patients, 10 had a favorable outcome after 3 months defined as full independence (Barthel index score of 100) or return to premorbid condition. One patient had a poor outcome with complete dependency due to reocclusion after primarily successful thrombolysis, and 1 patient died of severe brainstem infarction and additional space occupying parietal hemorrhage. CONCLUSIONS Favorable outcome could be achieved in the majority of 12 consecutive patients with moderate to severe vertebrobasilar ischemic stroke treated with intravenous recombinant tissue-type plasminogen activator within 3 hours after symptom onset.

UI MeSH Term Description Entries
D007269 Injections, Intra-Arterial Delivery of drugs into an artery. Injections, Intraarterial,Intra-Arterial Injections,Intraarterial Injections,Injection, Intra-Arterial,Injection, Intraarterial,Injections, Intra Arterial,Intra Arterial Injections,Intra-Arterial Injection,Intraarterial Injection
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D010960 Plasminogen Activators A heterogeneous group of proteolytic enzymes that convert PLASMINOGEN to FIBRINOLYSIN. They are concentrated in the lysosomes of most cells and in the vascular endothelium, particularly in the vessels of the microcirculation. Extrinsic Plasminogen Activators,Plasminogen Activator,Uterine-Tissue Plasminogen Activator,Uterine Tissue Plasminogen Activator
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute

Related Publications

M Grond, and J Rudolf, and S Schmülling, and C Stenzel, and M Neveling, and W D Heiss
November 2002, Orvosi hetilap,
M Grond, and J Rudolf, and S Schmülling, and C Stenzel, and M Neveling, and W D Heiss
March 2010, Stroke,
M Grond, and J Rudolf, and S Schmülling, and C Stenzel, and M Neveling, and W D Heiss
August 2015, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association,
M Grond, and J Rudolf, and S Schmülling, and C Stenzel, and M Neveling, and W D Heiss
January 2014, European neurology,
M Grond, and J Rudolf, and S Schmülling, and C Stenzel, and M Neveling, and W D Heiss
July 2014, Clinical neurology and neurosurgery,
M Grond, and J Rudolf, and S Schmülling, and C Stenzel, and M Neveling, and W D Heiss
June 2000, Stroke,
M Grond, and J Rudolf, and S Schmülling, and C Stenzel, and M Neveling, and W D Heiss
January 2000, Clinical neurosurgery,
M Grond, and J Rudolf, and S Schmülling, and C Stenzel, and M Neveling, and W D Heiss
January 2015, European neurology,
M Grond, and J Rudolf, and S Schmülling, and C Stenzel, and M Neveling, and W D Heiss
March 2009, Journal of clinical neurology (Seoul, Korea),
M Grond, and J Rudolf, and S Schmülling, and C Stenzel, and M Neveling, and W D Heiss
January 2021, American journal of translational research,
Copied contents to your clipboard!